Rhizoferrin Glycosylation in Rhizopus microsporus

0531142 - MBÚ 2020 RIV CH eng J - Článek v odborném periodiku
Škríba, Anton - Patil, Rutuja Hiraji - Hubáček, P. - Dobiáš, R. - Palyzová, Andrea - Marešová, Helena - Pluháček, Tomáš - Havlíček, Vladimír
Rhizoferrin Glycosylation in Rhizopus microsporus.
Journal of Fungi. Roč. 6, č. 2 (2020), č. článku 89. E-ISSN 2309-608X
Grant CEP: GA MŠMT(CZ) LO1509; GA ČR(CZ) GA19-10907S
Institucionální podpora: RVO:61388971
Klíčová slova: Rhizopus microsporus * glycoside * rhizoferrin
Obor OECD: Microbiology
Impakt faktor: 5.816, rok: 2020
Způsob publikování: Open access
https://www.mdpi.com/2309-608X/6/2/89

Rhizopus spp. are the most common etiological agents of mucormycosis, causing over 90% mortality in disseminated infections. The diagnosis relies on histopathology, culture, and/or polymerase chain reaction. For the first time, the glycosylation of rhizoferrin (RHF) was described in a Rhizopus microsporus clinical isolate by liquid chromatography and accurate tandem mass spectrometry. The fermentation broth lyophilizate contained 345.3 ± 13.5, 1.2 ± 0.03, and 0.03 ± 0.002 mg/g of RHF, imido-RHF, and bis-imido-RHF, respectively. Despite a considerable RHF secretion rate, we did not obtain conclusive RHF detection from a patient with disseminated mucormycosis caused by the same R. microsporus strain. We hypothesize that parallel antimycotic therapy, RHF biotransformation, and metabolism compromised the analysis. On the other hand, the full profile of posaconazole metabolites was retrieved by our in house software CycloBranch.
Trvalý link: http://hdl.handle.net/11104/0309879